Save 65,000 Breast Cancer Patients Six Months of Wasted Time and Toxic Exposure Each Year Direct Each Woman to the Right Chemotherapy for Her and Save the U.S. Health Care Sy stem $1.4 Billion in the Process
No company has cracked the code for choosing the best chemotherapy for an individual patient, despite the broad range of molecular breast cancer tests available today. Trial-and-error is still the mainstream available path. Currently, the majority of patients start their treatment journey with the ‘standard-of-care’, taxane-based regimen. Due to the low response rates to this regimen (25%) when patients are offered the next level of treatment they have already been exposed to side effects for about 6 months which is painful for patients (e.g., immune system debilitation, nausea, hair loss and exposure to unnecessary toxicity). Imagine if we knew who was a good candidate for the ‘standard-of-care’, and who should go straight to ‘Plan B’ while their immune systems are still strong?
Enter Bioarray Genetics, the CTSBDC’s own cancer revolutionary. Chemotherapy is not a “one-size-fits-all” process, and precision medicine was Marcia Fournier’s inspiration for founding her biotech company, BioArray Genetics. Marcia’s extensive experience in oncology, as well as her practical and strategic experience in drug discovery, biomarker development, and clinical diagnostics led to the development of BioArray’s first predictive test (BA100). It saves breast cancer patients potentially life-saving months, by pinpointing the best chemotherapy treatment for each patient based on genetic markers right out of the starting gate, while the patient’s body and immune system is still strong.
“I believe the predictive tests that BioArray is developing are exactly what is going to help propel programs like the Cancer Moonshot to ultimate success. Choosing the right chemotherapy is a little like choosing the right rocket engine: One size does not t all! You need the right t for your genetic type. Your life is on the line, and the clock is ticking. BioArray is revolutionizing cancer treatment selection, which is the key to finding individualized cures. It has been an honor to help Marcia and Pamela get the funding they need to propel their ground breaking research forward. They are an exceptional, innovative team, and this is precision medicine at its best.” — Patty Meagher, CTSBDC Technology Business Advisor
Ineffective and unnecessary treatments cost the U.S health care system $2.6 billion annually, waste precious time and can cost people their lives in the process. BioArray Genetic’s first innovative RNA-based predictive test identities which breast cancer patients will have a complete response to pre-surgical chemotherapy, resulting in over a 55 percent reduction in wasted treatments and a 68 percent improvement in response rates—not to mention its cost-effectiveness (the BA100 reduces the average cost of treating a patient in half, from $24,000 to $12,000). By properly identifying patients that will not respond to ‘standard-of-care’ chemotherapy, BioArray’s predictive test enables physicians to make the most beneficial and efficient decisions possible, and allows them to optimize and customize treatments for their patients enhancing outcomes and reducing costs simultaneously.
During the course of working with Patty Meagher of the CTSBDC, BioArray has raised the funding to create their exceptional technologies, which shine because of their unique ability to predict patient response to multiple treatments (immunotherapies, target-therapies in multiple types of cancer, etc.). Having secured this funding, the company has been able to initiate the development of five predictive tests in its pipeline, for breast, pancreatic and lung cancers.
Its unprecedented gene platform provides the broadest coverage of cell signaling pathways and drug associations to date. Because of this, BioArray is a valuable and robust complement to other gene platforms in the cancer drug research and development process. With some well-timed help from the CTSBDC, the company was able to round out its investor pool, and complete its Series A round of funding. Patty is on the Board of Astia and a member of the CT Angel Investor Forum, which is helpful in facilitating investor connections. Helping entrepreneurs navigate the mercurial waters of fundraising is what Patty spends the majority of her time doing as an advisor. She would be the first to say that entrepreneurship isn’t a solo act, it requires a team and it takes a lot of people opening up their personal networks to help startups along this journey.
Patty worked closely with the company to understand the value proposition and the technology resulting in intelligent connections with potential capital sources and industry leaders. She went above and beyond championing the company’s mission to help cancer patients by revolutionizing cancer treatment decisions. — Marcia Fournier, CEO BioArray Genetics
The company recently announced its last pre-market trial for the BA100 test, to be completed in collaboration with the University of Connecticut Health Center. This is the final milestone in the path to commercialization, and we are hopeful that the product should be publicly available by early 2018 if all goes as planned.
BioArray brings products from bench to bedside, and the company is on its way to transforming cancer treatment, and saving millions of lives, starting right here in Connecticut.Go Back